OESTRADIOL-P
-
| StockNo |
Product description |
| EB0280-445-08 |
OESTRADIOL-P
AMPOULE 10 ML/1ML (1%) |
-
- COMPOSITION:
Oestradiol dipropionate 10 mg/1 ml in one ampoule
ACTION:
A synthetic follicular hormone with the action of the natural
hormone oestradiol. Its properties of an oestrogen drug are more
pronounced, but it has a slower and more prolonged action. It is the
most active oestrogen substance and is assumed to be the primary
ovarian hormone. It is most active after subcutaneous application.
Its principal action is exercised on the genital organs (fallopian
tubes, uterus, endomerium, cervical canal) and on the determination
and development of the secondary sexual characters. It has a marked
role also in fat, protein and electrolyte metabolism. It influences
the hypophysis as a feedback. It exercises also a significant
influence on the processes in the brain cortex and on the vascular
tone (with vasodilating action).
PHARMACOKINETICS:
In plasma and tissues it is bound to specific proteins up to 50 %.
The connections are weak and allow an easy dissociation. It
metabolizes mainly in the liver. The preparation is excreted in a
very small part. Since it is bound to the proteins, it passes easily
into the CNS.
INDICATIONS:
The main indication of the preparation is insufficiency of the
endocrine activity of the ovaries in all its manifestations.
Consequences of ovarian insufficiency during climacterium and in
disturbances which may be due to a deficit of oestrogen hormones
(when that is proved radioimmunologically because the preparation
acts only as a substitute and not as an ovarian stimulator). For
inhibition of the function of the gonadotropic hormone. In carcioma
of the mammary gland (during menopause) and of the prostate gland.
CONTRAINDICATIONS:
Neoplastic (malign and benign) processes in the genital organs,
mammary glands, etc. (before the beginning of the profound
menopause). Mastropathy, endometritis, menstrual disorders as a
result of organic lesions in the genital apparatus. Hypertrophy in
the hyperfollicular stage of climacterium. |
SIDE EFFECTS:
The most frequent side effects are headache, tension in the mammary
glands, retention of water and salts. The more marked effects occur
after overdosage or prolonged treatment. They manifest themselves
with hyperplastic and later with metaplastic changes in the uterine
body and neck, in mammary glands.
PRECAUTIONS:
The cancerogenic effect of the oestrogen hormones necessitates a
careful application of the preparation, especially to women who have
a family history or a personal history of a malign disease of the
mammary glands or the genital organs. The preparation should not be
applied to women during the second half of the menstruation period.
DRUG INTERACTIONS:
The effects of oestradiol are reduced by butason, carbomasepin,
meprobamate; rifampicin, phenitoin, tamoxyphen. Oestradiol
diminishes the action of clofibrate, coumarine anticoagulants,
glucocorticoids, sulfonylurea, antidiabetic drugs. The oestradiol
toxicity is increased by tricylic antidepressants.
DOSAGE AND ADMINISTRATION:
The preparation is applied intramuscularly in strictly individual
doses, according to the disease. In disturbances of the menstruation
period - 5 injections of 0.05, every 3 days in 3 courses. In
hypoplasia of the uterus and sterility - 5 days in the first half of
the cycle. The climacteric disturbances are treated with 5
injections of 0.005, every 5-6 days.
MEDICINAL FORM AND PACKAGE:
Ampoules of 10 ml/l ml (1 %) in packs of 10 and 50.
STORAGE:
At moderate temperature (15-30° C) in a place protected from light.
In case there is a precipitate, the ampoule is warmed up until it
disappears.
EXPIRY:
3 (three) years.
|
